Last edition
News about "mesenchymal stromal cell (MSC) therapy "
Mesoblast Launches FDA-Approved Ryoncil for Pediatric Graft Versus Host Disease
Mesoblast has announced the commercial launch of Ryoncil (remestemcel-L-rknd) in the United States for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged two months and older.
Mesenchymal Stromal Cell (MSC) Therapy | 15/09/2025 | By Dineshwori | 143
Mesoblast Launches FDA-Approved Ryoncil for Pediatric Graft Versus Host Disease
Mesoblast has announced the commercial launch of Ryoncil (remestemcel-L-rknd) in the United States for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients aged two months and older.
Mesenchymal Stromal Cell (MSC) Therapy | 15/09/2025 | By Dineshwori | 143
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy